Wuhan Hamilton Biotechnology

Wuhan Hamilton Biotechnology is a clinical-stage biopharmaceutical company headquartered in Wuhan, China, dedicated to the development of advanced immunotherapy solutions, specifically chimeric antigen receptor (CAR) T-cell therapies. The company's research and development efforts are primarily focused on treating hematological malignancies and solid tumors through its proprietary cell engineering and manufacturing platforms. Hamilton Biotechnology's pipeline includes several promising CAR-T candidates targeting antigens such as CD19, BCMA, and CD22, with multiple programs currently in clinical trials. By integrating cutting-edge biotechnology with clinical research, the company aims to provide effective and accessible cell-based treatments for cancer patients. The firm operates a specialized GMP-compliant facility to support its clinical development and future commercialization needs.